2024-07-15 15:30 Regulatory
The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 15 July 2024 and the following resolutions were passed by the meeting. SHARE SAVINGS PROGRAM 2024/2027:1 FOR SENIOR EXECUTIVES AND...
2024-06-28 08:30 Regulatory
Biovica, a leader in blood-based cancer monitoring, has signed a Master Service Agreement and the initial Work Order with a US-based biopharmaceutical company specializing in breast cancer. The agreement enables Biovica to provide TKa testing services...
2024-06-28 08:00 Regulatory Annual
Annual report for the financial year 2023/2024 for Biovica International AB is published today on our website. See URL below. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: anders.rylander@biovica.com Anders Morén, CFOPhone: +46 73...
2024-06-27 10:30
The purpose of the extra general meeting that Biovica has called for on July 15, 2024, is to decide on share-based incentive programs for employees and the board of Biovica International AB and subsidiaries. By doing so at an extraordinary general meeting...
2024-06-27 09:00 Regulatory
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting to be held on Monday 15 July 2024, at 14:00 CET at Baker McKenzie's office at Vasagatan 7 in Stockholm...
2024-06-18 08:00 Regulatory Interim
Steadily increasing sales in the USA Significant events during the first three quarters Significant events during the fourth quarter Significant events after the end of the period Webcast:When: 18 June 2024, 3 PM to 4 PM CETWhere: registration via lyyti...
2024-05-30 08:30 Regulatory
Biovica, active in cancer diagnostics, today announces that results with DiviTum® TKa from the Spanish GEICAM/2014-12 FLIPPER trial will be presented at the world’s largest cancer conference, the annual ASCO meeting on June 2, 2024 9:00 AM &ndash...
2024-04-23 16:00 Regulatory
Biovica, active in blood-based cancer monitoring, announces a cost reduction program in Sweden and the US that will result in annual cost savings of approximately SEK 30 million and a restructuring cost of SEK 8 million. At the same time, Biovica is investigating...
2024-04-12 08:00 Regulatory
Biovica, active in cancer monitoring, today announces that a observational trial with DiviTum TKa has started at Mayo Clinic in Florida. If successful, it will further validate the utility of DiviTum TKa as an effective tool for disease monitoring. "The...
2024-04-11 08:00 Regulatory
The Nomination Committee prior to the 2024 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December...

>4,500

Numbers of patients in studies

28

Publications

19

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No